{"pmid":32503849,"title":"Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab.","text":["Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab.","Ann Rheum Dis","Avouac, Jerome","Airo, Paolo","Carlier, Nicolas","Matucci-Cerinic, Marco","Allanore, Yannick","32503849"],"journal":"Ann Rheum Dis","authors":["Avouac, Jerome","Airo, Paolo","Carlier, Nicolas","Matucci-Cerinic, Marco","Allanore, Yannick"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503849","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/annrheumdis-2020-217864","keywords":["inflammation","rituximab","scleroderma","systemic"],"e_drugs":["Rituximab"],"topics":["Case Report"],"weight":1,"_version_":1668892488298921986,"score":9.490897,"similar":[{"pmid":32503848,"title":"Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al.","text":["Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al.","Ann Rheum Dis","Guilpain, Philippe","Le Bihan, Clement","Foulongne, Vincent","Taourel, Patrice","Pansu, Nathalie","Maria, Alexandre Thibault Jacques","Jung, Boris","Larcher, Romaric","Klouche, Kada","Le Moing, Vincent","32503848"],"journal":"Ann Rheum Dis","authors":["Guilpain, Philippe","Le Bihan, Clement","Foulongne, Vincent","Taourel, Patrice","Pansu, Nathalie","Maria, Alexandre Thibault Jacques","Jung, Boris","Larcher, Romaric","Klouche, Kada","Le Moing, Vincent"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503848","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/annrheumdis-2020-217955","keywords":["b-lymphocytes","autoantibodies","rituximab"],"e_drugs":["Rituximab"],"weight":0,"_version_":1668892488319893504,"score":98.00398},{"pmid":32349982,"title":"Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.","text":["Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.","Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.","Ann Rheum Dis","Matucci-Cerinic, Marco","Bruni, Cosimo","Allanore, Yannick","Clementi, Massimo","Dagna, Lorenzo","Damjanov, Nemanja S","de Paulis, Amato","Denton, Christopher P","Distler, Oliver","Fox, David","Furst, Daniel E","Khanna, Dinesh","Krieg, Thomas","Kuwana, Masataka","Lee, Eun Bong","Li, Mengtao","Pillai, Shiv","Wang, Yukai","Zeng, Xiaofeng","Taliani, Gloria","32349982"],"abstract":["Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients."],"journal":"Ann Rheum Dis","authors":["Matucci-Cerinic, Marco","Bruni, Cosimo","Allanore, Yannick","Clementi, Massimo","Dagna, Lorenzo","Damjanov, Nemanja S","de Paulis, Amato","Denton, Christopher P","Distler, Oliver","Fox, David","Furst, Daniel E","Khanna, Dinesh","Krieg, Thomas","Kuwana, Masataka","Lee, Eun Bong","Li, Mengtao","Pillai, Shiv","Wang, Yukai","Zeng, Xiaofeng","Taliani, Gloria"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32349982","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/annrheumdis-2020-217407","keywords":["autoimmune diseases","hydroxychloroquine","scleroderma","systemic"],"topics":["Prevention"],"weight":1,"_version_":1666138495640403969,"score":96.659325},{"pmid":32312768,"title":"Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.","text":["Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.","Ann Rheum Dis","Guilpain, Philippe","Le Bihan, Clement","Foulongne, Vincent","Taourel, Patrice","Pansu, Nathalie","Maria, Alexandre Thibault Jacques","Jung, Boris","Larcher, Romaric","Klouche, Kada","Le Moing, Vincent","32312768"],"journal":"Ann Rheum Dis","authors":["Guilpain, Philippe","Le Bihan, Clement","Foulongne, Vincent","Taourel, Patrice","Pansu, Nathalie","Maria, Alexandre Thibault Jacques","Jung, Boris","Larcher, Romaric","Klouche, Kada","Le Moing, Vincent"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312768","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217549","keywords":["communicable diseases, imported","granulomatosis with polyangiitis","hydroxychloroquine","rituximab","systemic vasculitis"],"e_drugs":["Rituximab"],"topics":["Case Report"],"weight":1,"_version_":1666138493458317315,"score":85.614075},{"pmid":32354773,"title":"Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al.","text":["Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al.","Ann Rheum Dis","Monti, Sara","Montecucco, Carlomaurizio","32354773"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Montecucco, Carlomaurizio"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354773","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/annrheumdis-2020-217555","keywords":["autoimmunity","rituximab","systemic vasculitis"],"e_drugs":["Rituximab"],"weight":0,"_version_":1666138495168544770,"score":61.39451},{"pmid":32241792,"title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.","text":["COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.","Ann Rheum Dis","Mihai, Carina","Dobrota, Rucsandra","Schroder, Maria","Garaiman, Alexandru","Jordan, Suzana","Becker, Mike Oliver","Maurer, Britta","Distler, Oliver","32241792"],"journal":"Ann Rheum Dis","authors":["Mihai, Carina","Dobrota, Rucsandra","Schroder, Maria","Garaiman, Alexandru","Jordan, Suzana","Becker, Mike Oliver","Maurer, Britta","Distler, Oliver"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241792","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1136/annrheumdis-2020-217442","keywords":["biological therapy","communicable diseases, imported","cytokines","pulmonary fibrosis","scleroderma, systemic"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138492131868672,"score":46.47126}]}